This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Voxelotor oral


Oral formulations of voxelotor.

Drugs List

  • OXBRYTA 500mg tablets
  • voxelotor 500mg tablets
  • Therapeutic Indications


    Haemolytic anaemia in sickle cell disease

    Treatment of haemolytic anaemia due to sickle cell disease (HbSS) in adults and children aged 12 years and older as monotherapy or in combination with hydroxycarbamide.



    1.5g once daily.


    Children age 12 years and over
    1.5g once daily.

    Patients with Hepatic Impairment

    In patients with severe hepatic impairment (Child Pugh C) the recommended dose of voxelotor is 1g once daily.


    Children under 12 years

    Precautions and Warnings

    Patients over 65 years
    End stage renal disease
    Primary or secondary immunodeficiencies
    Severe hepatic impairment

    Reduce dose in patients with severe hepatic impairment
    Combination therapy: refer to information for concomitant agent
    Treatment to be prescribed under the supervision of a specialist
    Contains polyethylene glycol
    May affect results of some laboratory tests
    Discontinue permanently if severe hypersensitivity reactions occur
    Advise patient not to take St John's wort concurrently

    Safety and efficacy in sickle cell disease subtypes other than genotype HbSS or sickle beta-zero thalassemia are limited.

    Pregnancy and Lactation


    Voxelotor is contraindicated during pregnancy.

    The manufacturer advises that it is preferable to avoid the use of voxelotor during pregnancy. Animal data do not indicate direct or indirect harmful effects with respect to reproductive toxicity. The high protein binding of voxelotor (99.8% in vitro) should limit the embryo-fetal exposure. At the time of writing there are no or limited data from the use of voxelotor in pregnant women. The potential risk is unknown.


    Voxelotor is contraindicated during breastfeeding.

    The manufacturer does not recommend voxelotor during breastfeeding. Available data in animals have shown excretion of voxelotor in milk. It is unknown whether voxelotor or it metabolites are excreted in human milk. A risk to the newborn or infant cannot be excluded.

    Side Effects

    Abdominal pain
    Facial swelling
    Gastro-intestinal discomfort
    Hypersensitivity reactions
    Macular rash
    Papular eruption
    Pruritic rash
    Shortness of breath

    Effects on Laboratory Tests

    Voxelotor may interfere with the measurement of haemoglobin subtypes by high-performance liquid chromatography. If precise quantitation of Hb species is required, chromatography should be performed when the patient has not received voxelotor in the preceding 10 days.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2022

    Reference Sources

    Summary of Product Characteristics: Oxbryta 500mg film-coated tablets. Global Blood Therapeutics UK Limited. Revised July 2022.

    NICE Evidence Services Available at: Last accessed: 04 January 2023

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.